Skip to main content
. 2023 Mar 8;11(3):821. doi: 10.3390/biomedicines11030821

Figure 3.

Figure 3

KMT2A-r ALL—potential therapeutic targets discussed in the review. HDAC—histone deacetylase; FLT3—fms-like tyrosine kinase 3; CART T-cell—chimeric antigen receptor T-cell; HSCT—hematopoietic stem cell transplantation.